Profile data is unavailable for this security.
About the company
Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
- Revenue in PLN (TTM)157.00m
- Net income in PLN42.35m
- Incorporated2009
- Employees255.00
- LocationMabion SAgen. Mariana Langiewicza 60KONSTANTYNOW LODZKI 95-050PolandPOL
- Phone+48 422077890
- Fax+48 422032703
- Websitehttps://www.mabion.eu/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urteste SA | 0.00 | -5.62m | 139.56m | -- | -- | 4.84 | -- | -- | -4.74 | -4.74 | 0.00 | 20.47 | 0.00 | -- | -- | -- | -29.59 | -- | -30.60 | -- | -- | -- | -- | -- | 30.77 | -- | 0.0254 | -- | -- | -- | 3.38 | -- | -- | -- |
| Sds Optic SA | 530.40k | -7.39m | 164.57m | -- | -- | 23.47 | -- | 310.28 | -1.30 | -1.30 | 0.0928 | 1.19 | 0.054 | -5.91 | 2.11 | -- | -75.38 | -- | -94.39 | -- | 167.64 | -- | -1,395.87 | -- | 4.85 | -- | 0.00 | -- | -99.59 | -- | -85.26 | -- | -- | -- |
| Genomtec SA | 19.00k | -13.35m | 167.93m | -- | -- | 15.99 | -- | 8,838.58 | -1.32 | -1.32 | 0.0018 | 0.857 | 0.0014 | 24.23 | 0.0095 | -- | -95.96 | -- | -115.26 | -- | -12,973.68 | -- | -70,247.37 | -- | 4.05 | -31.75 | 0.1413 | -- | -81.72 | -- | -126.20 | -- | -- | -- |
| Poltreg SA | 1.40m | -13.55m | 240.63m | 18.00 | -- | 2.75 | -- | 172.00 | -2.91 | -2.91 | 0.300 | 18.77 | 0.0112 | 51.22 | 0.1876 | -- | -10.82 | -6.51 | -12.42 | -7.35 | -811.65 | -391.38 | -968.62 | -449.24 | 3.87 | -- | 0.0856 | -- | 40.04 | -- | -588.92 | -- | 214.26 | -- |
| Molecure SA | 1.31m | -18.31m | 251.53m | 111.00 | -- | 1.60 | -- | 192.22 | -1.17 | -1.17 | 0.0847 | 9.34 | 0.0085 | -- | 0.2818 | 11,788.92 | -11.94 | 2.52 | -12.47 | 2.64 | -25.76 | 97.54 | -1,398.86 | 12.84 | -- | -- | 0.0434 | -- | -18.85 | 237.24 | -19.67 | -- | -24.82 | -- |
| Mabion SA | 157.00m | 42.35m | 273.79m | 255.00 | 6.47 | 2.53 | 5.50 | 1.74 | 2.62 | 2.62 | 9.71 | 6.70 | 0.9539 | 8.23 | 28.36 | 615,701.90 | 25.73 | -24.92 | 34.58 | -79.97 | 61.40 | 46.13 | 26.97 | -73.93 | 1.88 | 4.33 | 0.0477 | -- | 188.33 | -- | 1,118.71 | -- | 18.66 | -- |
| Bioceltix SA | 0.00 | -12.73m | 279.98m | -- | -- | 19.67 | -- | -- | -3.45 | -3.45 | 0.00 | 3.45 | 0.00 | 170.52 | -- | -- | -112.58 | -- | -140.07 | -- | -- | -- | -- | -- | 5.96 | -- | 0.0071 | -- | -- | -- | -102.87 | -- | -- | -- |
| BIOTON SA | 181.64m | 2.28m | 300.52m | 358.00 | 132.13 | 0.4956 | 8.07 | 1.65 | 0.0265 | 0.0265 | 2.12 | 7.06 | 0.2228 | 0.9493 | 18.41 | 507,363.10 | 0.279 | -1.99 | 0.3437 | -2.47 | 40.11 | 45.33 | 1.25 | -8.61 | 0.2933 | 1.90 | 0.1018 | -- | -22.10 | -5.51 | 60.10 | -38.69 | 0.3284 | -- |
| Synthaverse SA | 58.61m | 4.76m | 321.73m | 239.00 | 72.80 | 3.08 | 28.25 | 5.49 | 0.0677 | 0.0677 | 0.8341 | 1.60 | 0.2732 | 1.66 | 2.76 | 245,217.60 | 2.22 | 3.53 | 2.55 | 4.32 | 60.00 | 55.62 | 8.12 | 9.59 | 0.9705 | 4.47 | 0.3834 | -- | 16.32 | 12.66 | -21.76 | -- | 111.77 | -- |
| Captor Therapeutics SA | 13.20m | -70.58m | 342.70m | 104.00 | -- | 5.45 | -- | 25.96 | -16.42 | -16.42 | 3.04 | 14.90 | 0.1256 | -- | 3.59 | 126,932.70 | -67.13 | -- | -82.96 | -- | 52.28 | -- | -534.69 | -- | -- | -- | 0.0518 | -- | 44.15 | -- | -96.65 | -- | -- | -- |
Data as of Apr 24 2024. Currency figures normalised to Mabion SA's reporting currency: Polish New Zloty PLN
4.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Generali PTE SAas of 29 Dec 2023 | 359.99k | 2.23% |
| Investors TFI SAas of 30 Jun 2023 | 197.50k | 1.22% |
| Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 2023 | 42.58k | 0.26% |
| ESALIENS TFI SAas of 30 Jun 2020 | 28.23k | 0.18% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 16.77k | 0.10% |
| IPOPEMA TFI SAas of 30 Jun 2023 | 1.67k | 0.01% |
| PKO TFI SAas of 31 Oct 2023 | 222.00 | 0.00% |
| TFI PZU SAas of 30 Jun 2020 | 0.00 | 0.00% |
| Santander Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 2020 | 0.00 | 0.00% |
| Rockbridge TFIas of 30 Jun 2020 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2020 - 31 Jan 2024Source: FactSet Research Systems Inc.
